MedCity News July 25, 2023
Frank Vinluan

Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.

The most common and easiest way to take medicine is by swallowing a pill. For a new class of therapies, dosing is even easier—just a few finger taps on a touchscreen. The now-defunct Pear Therapeutics was a pioneer among companies developing such software-based medicines.

Digital therapeutics engage users with apps and tasks that retrain and rewire the brain as a way of treating a range of diseases. This treatment is usually done alongside...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Apps, Clinical Trials, Digital Health, FDA, Govt Agencies, Insurance, Patient / Consumer, Payer, Provider, Technology, Trends
Search Funds growing interest in Healthcare Technology
HIMSS' priorities for 2025 focus on four areas
The Hinge Health S-1 Breakdown
Executive Insights: 4 Key Takeaways from HIMSS and ViVE 2025
5 Digital Health Areas To Be Impacted By The FDA Layoffs

Share This Article